@FiercePharma: Novartis Q2 shines on new meds, cost cuts. Report | Follow @FiercePharma
> Novartis has laid out its favorites to become blockbuster drugs from 2011 through 2015. Item
> A top physicians' group has voiced concern over the Australian federal government's new policy that could delay the approval of new drugs. News
> As the drug maker readies for a proxy battle with activist investor Carl Icahn, Forest Laboratories ($FRX) reported that its quarterly revenue came in a $1.15 billion compared with $1.07 billion in the year-ago quarter. Report
> The FDA has approved Dr Reddy's Laboratories' application for a generic palonosetron hydrochloride injection. Report
> Valeant Pharmaceuticals International ($VRX) has gained Canadian rights to Sanofi's ($SNY) knee pain ointment Zuacta. Article
Biotech News
@FierceBiotech: Do pharma BOD rosters clash with biotech strategy? Story | Follow @FierceBiotech
@JohnCFierce: Novartis listed its top 7 blockbuster prospects for '11-'15. Article | Follow @JohnCFierce
> Biogen Idec abandoning Wetson, plots move to Kendall Sq. More
> New study raises hopes for Pfizer, J&J Alzheimer's treatment. Item
> Pfizer adds to pain pipeline with $56M Icagen buyout. News
> AMAG and Allos to merge, readying the budget axe. Report
> Update: PwC tracks a spike in VC cash and deals for Biotechs. More
Drug Delivery News
> Magnetic nanosponges could ring in a new drug-delivery method. News
> New research might take the shine off gold nanoparticles. Report
> Alnylam, MIT team up for "binary" approach to delivering siRNA. Article
> Pills may replace inhalers in half of asthma cases. Story
Medical Device News
> FDA looks to regulate medical apps. Story
> Reports: Novartis no longer pursuing Gen-probe. Report
> Nevro completes $58M financing round. Article
> Roche to buy German's mtm for up to $184M. Item
And Finally... South African officials have made a controversial proposal to create a state-owned pharmaceutical company. Report